MTOR and tuberous sclerosis: Despite the lack of FDA-approved topical mTOR inhibitor in the United States at the time of survey, use of compounded topical rapamycin for the management of facial angiofibroma was reported by 105 (31.3%) caregivers and 23 (23.5%) patients with TSC (Fig. 3A).